In a 2013 study conducted by Shoshana Rosenberg, ScD, women younger than 40 with no increased genetic risk and disease in one breast believed that within five years, 10 out of 100 of them would develop it in the other.
E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine
significantly prolonged progression-free survival in patients with progressive
HER2-positive advanced breast cancer.
Eric P. Winer co-chaired an expert panel that developed a clinical practice
guideline on disease management for patients with advanced HER2-positive breast
cancer and brain metastases.
Tags: BreastCancer, Surgery
Dr. Ann Partridge comments on the misunderstandings of breast cancer risks that are leading women to double mastectomies.
Tags: BreastCancer, OvarianCancer, Genetics
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: